ダウンロード数: 650
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
66_5_147.pdf | 648.74 kB | Adobe PDF | 見る/開く |
タイトル: | ニボルマブ投与により著明な免疫関連有害事象と, 中止後の持続的腫瘍縮小を認めた転移性腎細胞癌の1例 |
その他のタイトル: | Durable Response after Discontinuation Due to Immune-Related Adverse Events in a Patient with Metastatic Clear Cell Renal Cell Carcinoma : A Case Report |
著者: | 植木, 洋平 田中, 俊明 橋本, 浩平 小林, 皇 福多, 史昌 舛森, 直哉 |
著者名の別形: | Ueki, Yohei Tanaka, Toshiaki Hashimoto, Kohei Kobayashi, Ko Fukuta, Fumimasa Masumori, Naoya |
キーワード: | Nivolumab Durable response Immune-related adverse events |
発行日: | 31-May-2020 |
出版者: | 泌尿器科紀要刊行会 |
誌名: | 泌尿器科紀要 |
巻: | 66 |
号: | 5 |
開始ページ: | 147 |
終了ページ: | 151 |
抄録: | A 70-year-old female with metastatic clear cell renal cell carcinoma was treated with nivolumab. After three dosages, she developed interstitial lung disease which required steroid therapy and nivolumab was discontinued. Thereafter, the target lesion continued to shrinkand the best response was partial response 15 weeks after discontinuation of nivolumab, the reduction rate of which eventually reached 49.1%. Other immune-related adverse events (irAEs), nephrotic syndrome and acute kidney injury developed 34 weeks after discontinuation of nivolumab, leading to irreversible kidney injury that required chronic hemodialysis. Although the target lesion continued to shrink, a new lesion developed 48 weeks after discontinuation of nivolumab. Subsequently, targeted therapies were added, but she died of cancer 13 months after resuming medical treatment. In this case, although various irAEs developed, the effectiveness of nivolumab was sustained even after it was discontinued. |
著作権等: | 許諾条件により本文は2021/06/01に公開 |
DOI: | 10.14989/ActaUrolJap_66_5_147 |
URI: | http://hdl.handle.net/2433/251060 |
PubMed ID: | 32483950 |
出現コレクション: | Vol.66 No.5 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。